Denosumab-induced Normocalcemic Hyperparathyroidism in a Woman with Postmenopausal Osteoporosis and Normal Renal Function

Publisher： Bentham Science Publishers

E-ISSN： 2212-3911|13|3|214-216

ISSN： 1574-8863

Source： Current Drug Safety, Vol.13, Iss.3, 2018-11, pp. : 214-216

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis

By Josse Robert   Khan Aliya   Ngui Daniel   Shapiro Marla  

Current Medical Research and Opinion, Vol. 29, Iss. 3, 2013-03 ,pp. : 205-216

Informa Healthcare

Access to resources Recommend Favorite

Clinical use of denosumab for the treatment for postmenopausal osteoporosis

By Lewiecki E. Michael  

Current Medical Research and Opinion, Vol. 26, Iss. 12, 2010-12 ,pp. : 2807-2812

Informa Healthcare

Access to resources Recommend Favorite

Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis

By Jönsson B.   Ström O.   Eisman J.   Papaioannou A.   Siris E.   Tosteson A.   Kanis J.  

Osteoporosis International, Vol. 22, Iss. 3, 2011-03 ,pp. : 967-982

Springer Publishing Company

Access to resources Recommend Favorite

CATHARTIC‐INDUCED LIFE THREATENING HYPERMAGNESEMIA IN A 90‐YEAR‐OLD WOMAN WITH APPARENT NORMAL RENAL FUNCTION

By  

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 47, Iss. 8, 1999-08 ,pp. : 1039-1040

John Wiley & Sons Inc

Access to resources Recommend Favorite

Denosumab‐induced cutaneous hypersensitivity reaction with distinct clinical and histopathologic findings

By  

JOURNAL OF CUTANEOUS PATHOLOGY, Vol. 45, Iss. 2, 2018-02 ,pp. : 156-158

John Wiley & Sons Inc

Access to resources Recommend Favorite